Clinical Trial Update: Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

View source ↗

Summary

Trial exploring whether DNA repair pathway alterations affect Radium-223 efficacy in bone-metastatic castration-resistant prostate cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (Xofigo) (radium-223 dichloride)

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Status: RECRUITING